Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.51 |
| ▸ | GLS | O94925 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL517469 | 0.90 | TDP1 (0.53) | CASP3RAB9ASMN1; SMN2MAPTTDP1 | |
| Bromide SCHEMBL29425571 | 0.90 | TDP1 (0.53) | CASP3RAB9ASMN1; SMN2MAPTTDP1 | |
| Bromide SCHEMBL1325100 | 0.88 | TDP1 (0.55) | RAB9ASMN1; SMN2MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL1579652 | 0.87 | TDP1 (0.58) | RAB9ASMN1; SMN2MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL20541913 | 0.87 | TDP1 (0.58) | RAB9ASMN1; SMN2MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL20541546 | 0.87 | TDP1 (0.58) | RAB9ASMN1; SMN2MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL20541389 | 0.87 | TDP1 (0.58) | RAB9ASMN1; SMN2MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL20541445 | 0.87 | TDP1 (0.58) | RAB9ASMN1; SMN2MAPTTDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4887656 | 0.78 | CASP3 (0.49) | CASP3GLSRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14764997 | 0.77 | TDP1 (0.50) | ALDH1A1TDP1L3MBTL1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014172871-A1 | DIHYDROBENZOFURAN DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-30 | — | — | WO | disclosed |
| US-8815920-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8669246-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-09-05 | — | — | US | disclosed |
| EP-2481725-A1 | SUBSTITUTED AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-0931060-A4 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | AVENTIS PHARMA INC (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-0861243-B1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-11-12 | — | — | EP | disclosed |
| US-6344462-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| US-6323227-B1 | PRODRUGS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-11-27 | — | — | US | disclosed |
| US-6100284-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6008229-A | TREATING ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0931060-A1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999000356-A1 | SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | CHRM2 86/4885CASP3 3921/4885GLS 3109/4885 |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | CHRM2 87/4885CASP3 3884/4885GLS 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.